AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32650223 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (weight loss program)
Number of subjects: 47
Study 32650223 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (control)
Number of subjects: 47
Study 32650223 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SCS
Number of subjects: 47
Study 35903009 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (10 mg)
Number of subjects: 31
Study 35903009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 34006926 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib 12 mg orally once daily for 14 days every 3 weeks
Number of subjects: 120
Study 34006926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 32909491 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person training
Number of subjects: 441
Study 32909491 — intervention group
Group type: COMPARATOR
Intervention: Virtual tele-mentoring
Number of subjects: 441
Study 32909491 — intervention group
Group type: EXPERIMENTAL
Intervention: Training (both methods)
Number of subjects: 441
Study 32909491 — intervention group
Group type: EXPERIMENTAL
Intervention: SOuND practices
Number of subjects: 441
Study 36269383 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix‐associated autologous chondrocyte implantation (ACI) using spheroids (n=52)
Number of subjects: 102
Study 36269383 — intervention group
Group type: COMPARATOR
Intervention: Microfracture (n=50)
Number of subjects: 102
Study 34474735 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal Denervation (RDN)
Number of subjects: 0
Study 34474735 — intervention group
Group type: COMPARATOR
Intervention: Sham Control
Number of subjects: 0
Study 36346543 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention involving referral to treating physician for therapy intensification.
Number of subjects: 497
Study 36346543 — intervention group
Group type: COMPARATOR
Intervention: Control group (AOBP recorded until the end of the trial).
Number of subjects: 497
Study 36346543 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control).
Number of subjects: 497
Study 33576770 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher supine systolic blood pressure
Number of subjects: 231
Study 33576770 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher supine diastolic blood pressure
Number of subjects: 231
Study 33576770 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher augmentation index
Number of subjects: 231
Study 33576770 — intervention group
Group type: EXPERIMENTAL
Intervention: Central systolic pressure and arterial stiffness indicators (including pulse wave velocity, central pulse pressure, and peripheral pulse pressure)
Number of subjects: 231
Study 32457373 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory meetings (20-minute meetings once per week for six weeks)
Number of subjects: 1924
Study 32457373 — intervention group
Group type: COMPARATOR
Intervention: Status quo meetings
Number of subjects: 1924
Study 35257151 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant pembrolizumab
Number of subjects: 0
Study 35257151 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant ipilimumab
Number of subjects: 0
Study 35257151 — intervention group
Group type: COMPARATOR
Intervention: IFNα2b
Number of subjects: 0
Study 32564634 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study 32564634 — intervention group
Group type: COMPARATOR
Intervention: Non-dexamethasone
Number of subjects: 0
Study 33694035 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime CPAP application (30-60 min)
Number of subjects: 246
Study 33694035 — intervention group
Group type: COMPARATOR
Intervention: Usual care (first CPAP application on titration night)
Number of subjects: 246
Study 33694035 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime CPAP application
Number of subjects: 246
Study 33694035 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 246
Study 35175357 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 202
Study 35175357 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical treatment
Number of subjects: 202
Study 32716500 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV20
Number of subjects: 444
Study 32716500 — intervention group
Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 444
Study 32676134 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (12 sessions, 20 minutes each over 4 weeks)
Number of subjects: 40
Study 32676134 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B1 (300 mg tablet) and Gabapentin (300 mg capsules, 3 per day for 4 weeks)
Number of subjects: 40
Study 35588357 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus breathing exercises (UC + BrEX)
Number of subjects: 193
Study 34852103 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Counseling Intervention (BCI)
Number of subjects: 61
Study 34852103 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Physical Exercise Intervention (SPEI)
Number of subjects: 61
Study 34852103 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 61
Study 36429394 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical nutrition therapy/counseling and nutrition education
Number of subjects: 38
Study 36429394 — intervention group
Group type: COMPARATOR
Intervention: Educational material related to nutrition, HIV, and prediabetes
Number of subjects: 38
Study 34312823 — intervention group
Group type: EXPERIMENTAL
Intervention: Early albumin administration (within the initial 24 perioperative hours)
Number of subjects: 735
Study 32460840 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group-based stabilization and skill-training (SST) intervention added to individual treatment
Number of subjects: 160
Study 32460840 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 160
Study 35351194 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tanezumab (2.5mg or 5mg every 8 weeks)
Number of subjects: 0
Study 35351194 — intervention group
Group type: COMPARATOR
Intervention: Oral NSAID (twice daily naproxen, celecoxib, or diclofenac)
Number of subjects: 0
Study 33499864 — intervention group
Group type: EXPERIMENTAL
Intervention: mhealth messages and environmental cues
Number of subjects: 450
Study 33499864 — intervention group
Group type: COMPARATOR
Intervention: HH facilities and supplies (Control)
Number of subjects: 450
Study 32192742 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Transverse Abdominal Plane (TAP) block with ropivacaine 0.375% 20 mL and ropivacaine 0.2%
Number of subjects: 30
Study 32192742 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Transverse Abdominal Plane (TAP) block
Number of subjects: 30
Study 32192742 — intervention group
Group type: COMPARATOR
Intervention: Continuous Epidural Analgesia with ropivacaine 0.2%
Number of subjects: 30
Study 35999043 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐Fio2
Number of subjects: 44
Study 35999043 — intervention group
Group type: COMPARATOR
Intervention: M‐Fio2
Number of subjects: 44
Study 34446493 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 500
Study 34446493 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention materials (after 1 month wait)
Number of subjects: 500
Study 32705504 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg
Number of subjects: 200
Study 32705504 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 200
Study 32705504 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 healthy individuals)
Number of subjects: 200
Study 32976869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ralimetinib (100 mg/12 h) with chemoradiotherapy (RT 60 Gy in 30 fractions and TMZ 75 mg/m2/day)
Number of subjects: 18
Study 32976869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ralimetinib (200 mg/12 h)
Number of subjects: 18
Study 32976869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ralimetinib (300 mg/12 h)
Number of subjects: 18
Study 32976869 — intervention group
Group type: COMPARATOR
Intervention: Standard concurrent RT and TMZ
Number of subjects: 18
Study 32086341 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 1548
Study 35847230 — intervention group
Group type: EXPERIMENTAL
Intervention: CarFreeMe TI program (six-week group-based support and education program)
Number of subjects: 20
Study 35847230 — intervention group
Group type: COMPARATOR
Intervention: Standard information related to transport options available (control)
Number of subjects: 20
Study 34336152 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin (RAPA)
Number of subjects: 316
Study 34620739 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection into the flexor digitorum brevis and quadratus plantae
Number of subjects: 35
Study 34620739 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection
Number of subjects: 35
Study 34620739 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection (methylprednisolone) into the plantar fascia
Number of subjects: 35
Study 33560244 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth app and chest-wearable remote exercise monitoring; participants followed exercise videos on the app and wore a chest band for 3 months.
Number of subjects: 101
Study 33560244 — intervention group
Group type: COMPARATOR
Intervention: Control group self-reported exercise intensity and duration; participants engaged in traditional exercise for 3 months.
Number of subjects: 101
Study 36267745 — intervention group
Group type: EXPERIMENTAL
Intervention: H-VA (high-dose amoxicillin combined with VPZ): VPZ 20 mg b.i.d with amoxicillin 750 mg q.i.d for 7 days
Number of subjects: 230
Study 36267745 — intervention group
Group type: EXPERIMENTAL
Intervention: L-VA (low-dose amoxicillin combined with VPZ): VPZ 20 mg b.i.d plus amoxicillin 500 mg q.i.d for 7 days
Number of subjects: 230
Study 36267745 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC (amoxicillin combined with VPZ and clarithromycin): VPZ 20 mg b.i.d plus amoxicillin 750 mg plus clarithromycin 500 mg for 7 days
Number of subjects: 230
Study 32529596 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Walking
Number of subjects: 32
Study 32529596 — intervention group
Group type: COMPARATOR
Intervention: Walking
Number of subjects: 32
Study 33608936 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine (VCR)
Number of subjects: 59
Study 35728557 — intervention group
Group type: EXPERIMENTAL
Intervention: Water cleaning method
Number of subjects: 0
Study 35728557 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush cleaning method
Number of subjects: 0
Study 35728557 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton swab cleaning method
Number of subjects: 0
Study 35728557 — intervention group
Group type: EXPERIMENTAL
Intervention: EnClean® brush cleaning method
Number of subjects: 0
Study 35728557 — intervention group
Group type: COMPARATOR
Intervention: Uncleaned control
Number of subjects: 0
Study 33493193 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy-induced hypertension
Number of subjects: 516
Study 33493193 — intervention group
Group type: EXPERIMENTAL
Intervention: One time ANC visits
Number of subjects: 516
Study 33493193 — intervention group
Group type: EXPERIMENTAL
Intervention: Premature rupture of membrane
Number of subjects: 516
Study 33493193 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth interval less than two years
Number of subjects: 516
Study 33493193 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia during current pregnancy
Number of subjects: 516
Study 33493193 — intervention group
Group type: EXPERIMENTAL
Intervention: No dietary supplementation during current pregnancy
Number of subjects: 516
Study 35406052 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary weight loss
Number of subjects: 137
Study 32931045 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemplary hygiene practices (Condition 2)
Number of subjects: 65
Study 32931045 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor hygiene practices (Condition 1)
Number of subjects: 65
Study 32931045 — intervention group
Group type: COMPARATOR
Intervention: Control condition (Condition 3)
Number of subjects: 65
Study 36157391 — intervention group
Group type: EXPERIMENTAL
Intervention: VFR with low frequency (35 Hz)
Number of subjects: 16
Study 36157391 — intervention group
Group type: EXPERIMENTAL
Intervention: VFR with high frequency (67 Hz)
Number of subjects: 16
Study 35338131 — intervention group
Group type: EXPERIMENTAL
Intervention: PvCS formulated in Montanide ISA‐51 adjuvant
Number of subjects: 35
Study 35338131 — intervention group
Group type: COMPARATOR
Intervention: Placebo (adjuvant alone)
Number of subjects: 35
Study 33535338 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program (CDSMP) for 6 months
Number of subjects: 358
Study 33535338 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 358
Study 33164941 — intervention group
Group type: EXPERIMENTAL
Intervention: Pridopidine 45 mg bid
Number of subjects: 0
Study 33164941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33920971 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention focusing on reducing sedentariness
Number of subjects: 263
Study 33920971 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention focusing on increasing physical activity
Number of subjects: 263
Study 33920971 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 263
Study 33579317 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 22
Study 33579317 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 22
Study 33579317 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 22
Study 33579317 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 22
Study 33103389 — intervention group
Group type: EXPERIMENTAL
Intervention: Mozart music
Number of subjects: 9
Study 33103389 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnic music
Number of subjects: 9
Study 33103389 — intervention group
Group type: COMPARATOR
Intervention: No music
Number of subjects: 9
Study 33870833 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 35686460 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg/kg) + Acute Intermittent Hypoxia (AIH; FIO2=0.10)
Number of subjects: 12
Study 35686460 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Acute Intermittent Hypoxia (AIH; FIO2=0.10)
Number of subjects: 12
Study 35686460 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg/kg) + SHAM (FIO2=0.21)
Number of subjects: 12
Study 33582533 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic index diet therapy (LGIT) for 3 months along with ongoing antiepileptic drugs
Number of subjects: 40
Study 33582533 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 40
Study 33582533 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic index diet therapy (LGIT)
Number of subjects: 40
Study 36279581 — intervention group
Group type: EXPERIMENTAL
Intervention: Early division group
Number of subjects: 70
Study 36279581 — intervention group
Group type: COMPARATOR
Intervention: Conventional division group
Number of subjects: 70
Study 34329580 — intervention group
Group type: EXPERIMENTAL
Intervention: Current approaches to risk stratification and treatment of polycythaemia vera
Number of subjects: 0
Study 34076644 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralized plasmatic matrix grafts (MPM)
Number of subjects: 26
Study 33822986 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy to both prostate and metastatic regions
Number of subjects: 35
Study 34196980 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-hypertensive use
Number of subjects: 1932
Study 33509113 — intervention group
Group type: EXPERIMENTAL
Intervention: Everyday Cognition Training Programme
Number of subjects: 237
Study 33509113 — intervention group
Group type: COMPARATOR
Intervention: Conventional Cognitive Training Programme
Number of subjects: 237
Study 35076698 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CCP) treatment
Number of subjects: 2287
Study 35076698 — intervention group
Group type: COMPARATOR
Intervention: Control (no CCP treatment)
Number of subjects: 2287
Study 33219473 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical therapy
Number of subjects: 100
Study 33219473 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic-driven therapy
Number of subjects: 100
Study 33219473 — intervention group
Group type: EXPERIMENTAL
Intervention: ANC < 0.1 × 10^9/L
Number of subjects: 100
Study 33219473 — intervention group
Group type: COMPARATOR
Intervention: ANC ≥ 0.1 × 10^9/L
Number of subjects: 100
Study 32890282 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit SBP variability (measured as coefficient of variation)
Number of subjects: 28790
Study 32890282 — intervention group
Group type: EXPERIMENTAL
Intervention: On-treatment mean SBP
Number of subjects: 28790
Study 32890282 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of SBP-CV and mean SBP quintiles
Number of subjects: 28790
Study 32890282 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial micro or macroalbuminuria
Number of subjects: 28790
Study 35487708 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicines at Transition Intervention (MaTI)
Number of subjects: 2100
Study 35487708 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 2100
Study 33892217 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-guided treatment
Number of subjects: 530
Study 35410433 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbrokinase plus aspirin
Number of subjects: 220
Study 35410433 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus aspirin
Number of subjects: 220
Study 34233378 — intervention group
Group type: EXPERIMENTAL
Intervention: 595-nm pulsed dye laser (PDL) treatment with oxymetazoline cream
Number of subjects: 34
Study 34233378 — intervention group
Group type: COMPARATOR
Intervention: oxymetazoline cream alone
Number of subjects: 34
Study 35762297 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser
Number of subjects: 30
Study 35762297 — intervention group
Group type: COMPARATOR
Intervention: Carboxytherapy
Number of subjects: 30
Study 32247586 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic pancreaticoduodenectomy (RPD)
Number of subjects: 103
Study 35429351 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser+SE-FS
Number of subjects: 60
Study 35429351 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid-etch+SE-FS
Number of subjects: 60
Study 35429351 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser+Acid-etch+SE-FS
Number of subjects: 60
Study 35429351 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical preparation+SE-FS
Number of subjects: 60
Study 35429351 — intervention group
Group type: EXPERIMENTAL
Intervention: SE-FS
Number of subjects: 60
Study 35429351 — intervention group
Group type: COMPARATOR
Intervention: Acid-etch+Bonding+Conventional fissure sealant
Number of subjects: 60
Study 33478433 — intervention group
Group type: EXPERIMENTAL
Intervention: OB Nest prenatal care (telemedicine-enhanced with reduced in-person visits)
Number of subjects: 0
Study 33478433 — intervention group
Group type: COMPARATOR
Intervention: Traditional prenatal care
Number of subjects: 0
Study 33478433 — intervention group
Group type: EXPERIMENTAL
Intervention: OB Nest prenatal care
Number of subjects: 0
Study 32576228 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mL/day soy milk plus routine treatments
Number of subjects: 30
Study 32576228 — intervention group
Group type: COMPARATOR
Intervention: Routine treatments only
Number of subjects: 30
Study 33021402 — intervention group
Group type: EXPERIMENTAL
Intervention: After-Action Reviews (AARs)
Number of subjects: 84
Study 33021402 — intervention group
Group type: COMPARATOR
Intervention: Non-After-Action Reviews (non-AAR)
Number of subjects: 84
Study 33249759 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 206
Study 33249759 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 206
Study 35397292 — intervention group
Group type: EXPERIMENTAL
Intervention: Duavee® (bazedoxifene + conjugated estrogen)
Number of subjects: 24
Study 35397292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 34083233 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA-positive patients (n=140)
Number of subjects: 1017
Study 34083233 — intervention group
Group type: COMPARATOR
Intervention: ctDNA-negative patients (n=877)
Number of subjects: 1017
Study 34083233 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA as an independent prognostic marker for DFS
Number of subjects: 1017
Study 34083233 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA as an independent prognostic marker for OS
Number of subjects: 1017
Study 34083233 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA in patients treated for 3 months with T4 and/or N2 tumors
Number of subjects: 1017
Study 34083233 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA in patients treated for 6 months with T1-3/N1 tumors
Number of subjects: 1017
Study 34426075 — intervention group
Group type: EXPERIMENTAL
Intervention: Pigtail catheter group
Number of subjects: 1375
Study 34426075 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1375
Study 32540624 — intervention group
Group type: EXPERIMENTAL
Intervention: Handlebars (control plus two red rear‐facing lights on each handlebar)
Number of subjects: 14
Study 32540624 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet (control plus one red rear‐facing light on the helmet)
Number of subjects: 14
Study 32540624 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg Retro‐reflectors (control plus retro‐reflective strips positioned on the knees and ankles)
Number of subjects: 14
Study 32540624 — intervention group
Group type: COMPARATOR
Intervention: Control (red rear‐facing light and reflector)
Number of subjects: 14
Study 32540624 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 14